BioStock: PHI part of new regenerative medicine alliance

November 16, 2022
Language flag

Swedish medtech company Phase Holographic Imaging (PHI) has created a technology development alliance with key industry players: Wake Forest Institute for Regenerative Medicine, BioSpherix, QIAGEN and global analytics company SAS. By creating the AI-based process control tools needed for automated biomanufacturing, cell-based therapies could be manufactured cost-effectively with optimized efficacy and safety. BioStock reached out to PHI’s Product Manager Lisa Lindström to learn more.

Read the full interview with Lisa Lindström on biostock.se.

Latest News

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 December 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

The Board of Directors of Phase Holographic Imaging PHI AB has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024. The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company’s capital structure by repayment/off-setting of outstanding loans.

Adopting the final Annual Report

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
See All News